Denise Carter - Sep 3, 2024 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role: Chief Operating Officer, Director
Signature: /s/ Denise Carter
Stock symbol: QNRX
Transactions as of: Sep 3, 2024
Transactions value $: $28,737
Form type: 4
Date filed: 9/5/2024, 12:06 PM
Previous filing: Oct 30, 2023
Next filing: Dec 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNRX	Ordinary Shares	Purchase	$1.14K	+1.82K	+19.47%	$0.63	11.2K	Sep 3, 2024	Direct	F1, F2
transaction	QNRX	Ordinary Shares	Purchase	$2.69K	+4.1K	+36.68%	$0.66	15.3K	Sep 3, 2024	Direct	F1
transaction	QNRX	Ordinary Shares	Purchase	$6.6K	+8.83K	+57.76%	$0.75	24.1K	Sep 4, 2024	Direct	F1
transaction	QNRX	Ordinary Shares	Purchase	$18.3K	+23K	+95.37%	$0.80	47.1K	Sep 4, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.
F2	Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023.

Content

Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.

Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023.